Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Patent
1995-06-06
1998-10-27
Hendricks, Keith D.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
514 12, A61K 3817
Patent
active
058278168
ABSTRACT:
Disclosed are novel bactericidal/permeability-increasing (BPI) protein products wherein cysteine residue number 132 or 135 is replaced by another amino acid residue, preferably an alanine or serine residue and/or wherein the leucine residue at position 193 is the carboxy terminal residue. Also disclosed are DNA sequences encoding methods for the production of the same in appropriate host cells, and stable homogeneous pharmaceutical compositions containing the analogs suitable for use treatment of gram negative bacterial infection and its sequelae.
REFERENCES:
patent: Re33653 (1991-07-01), Mark et al.
patent: 4518584 (1985-05-01), Mark et al.
patent: 4588585 (1986-05-01), Mark et al.
patent: 4677063 (1987-06-01), Mark et al.
patent: 4677064 (1987-06-01), Mark et al.
patent: 4816566 (1989-03-01), DeChiara et al.
patent: 4853332 (1989-08-01), Mark et al.
patent: 4879226 (1989-11-01), Wallace et al.
patent: 4959314 (1990-09-01), Mark et al.
patent: 5089274 (1992-02-01), Marra et al.
patent: 5171739 (1992-12-01), Scott
patent: 5198541 (1993-03-01), Elsbach et al.
patent: 5206344 (1993-04-01), Katre et al.
patent: 5234912 (1993-08-01), Marra et al.
patent: 5308834 (1994-05-01), Scott et al.
patent: 5334584 (1994-08-01), Scott et al.
patent: 5348942 (1994-09-01), Little, II et al.
Bebbington et al., "High-Level Expression of a Recombinant Antibody from Myeloma Cells Using a Glutamine Synthetase Gene as an Amplifiable Selectable Marker", Bio/Technology, 10(2):169-175 (Feb. 1992).
Boshart et al., "A Very Strong Enhancer is Located Upstream of an Immediate Early Gene of Human Cytomegalovirus", Cell 41:521-530 (Jun. 1985).
Elsbach et al., "Separation and Purification of a Potent Bactericidal/Permeability-increasing Protein and a Closely Associated Phospholipase A.sub.2 from Rabbit Polymorphonuclear Leukocytes", J. Biol. Chem., 254(21):11000-11009 (Nov. 10, 1979).
Gazzano-Santoro et al., "High-Affinity Binding of the Bactericidal/Permeability-Increasing Protein and a Recombinant Amino-Terminal Fragment to the Lipid A Region of Lipopolysaccharide", Infect. Immun. 60(11):4754-4761 (Nov. 1992).
Gray et al., "Cloning of the cDNA of a Human Neutrophil Bactericidal Protein", J. Biol. Chem., 264(16):9505-9509 (Jun. 5, 1989).
Habuka et al., "Substantial Increase of the Inhibitory Activity of Mirabilis Antiviral Protein by an Elimination of the Disulfide Bond with Genetic Engineering", J. Biol. Chem., 266(35):23558-23560 (Dec. 15, 1991).
Hartman and Mulligan, "Two dominant-acting selectable markers for gene transfer studies in mammalian cells", Proc. Nat. Acad. Sci. USA, 85:8047-8051 (Nov. 1988).
Kaback, "Use of Site-Directed Mutagenesis to Study the Mechanism of a Membrane Transport Protein", Biochemistry, 26(8):2071-2076 (Apr. 21, 1987).
Kozak, "An analysis of 5'-noncoding sequences from 699 vertebrate messenger RNAs", Nucl. Acid. Res., 15(20):8125-8148 (1987).
Lambert et al., "Recombinant Bactericidal/Permeability-Increasing (rBPI) Protein Kills both Gram-Positive and Gram-Negative Bacteria", Abstracts of the 34th Interscience Conference on Antimicrobial Agents and Chemotherapy, Abstract #C/6 (Oct. 4-7 1994).
Liang et al., "Studies of Structure-Activity Relationships of Human Interleukin-2", J. Biol. Chem., 261(1):334-337 (Jan. 5, 1986).
Lui et al., "Production of a Mouse-Human Chimeric Monoclonal Antibody to CD20 with Potent Fc-Dependent Biologic Activity", J. Immunol., 139(10):3521-3526 (Nov. 15, 1987).
Mark et al., "Site-specific mutagenesis of the human fibroblast interferon gene", Proc. Natl. Acad. Sci. USA, 81:0000-0000 (Sep. 1984).
Morrison, "The case for specific lipopolysaccharide receptors expressed on mamalian cells", Microb. Pathogenesis, 7:389-398 (1989).
Morrison and Ryan, "Endotoxins and Disease Mechanisms", Ann. Rev. Med., 38:417-432 (1987).
Mulligan and Berg, "Selection for animal cells that express the Escherichia coli gene coding for xanthine-guanine phosphoribosyltransferase", Proc. Nat. Acad. Sci. USA, 78(4):2072-2076 (Apr. 1981).
Ooi et al., "Endotoxin-neutralizing Properties of the 25 kD N-Terminal Fragment and a Newly Isolated 30 kD C-Terminal Fragment of the 55-60 kD Bactericidal/Permeability-increasing Protein of Human Neutrophils", J. Exp. Med., 174:649-655 (Sep. 1991).
Perry and Wetzel, "unpaired Cysteine-54 Interferes with the Ability of an Enginered Disulfide to Stabilize T4 Lysozyme", Biochemistry, 25(3):733-739 (1986).
Raetz, "Biochemistry of Endotoxins", Ann. Rev. Biochem., 59:129-170 (1990).
Rastetter, "Enzyme engineering: applications and Promise", Trends Biotech. 1(3) (1983).
Roeder et al., "Endotoxic-Lipopolysaccharide-Specific Binding Proteins on Lymphoid Cells of Various Animal Species: Association with Endotoxin Susceptibility", Infect., Immun., 57(4):1054-1058 (Apr. 1989).
Rusk et al., "Structure-Function Relationships for the IL-2 Receptor System", J. Immunol., 140(7):2249-2259 (Apr. 1, 1988).
Sambrook et al., "Introduction of Recombinant Vectors into Mammalian Cells", in Molecular Cloning: A Labratory Manual, pp. 16.30-16.31 (1989).
Shepard et al., "A single amino acid change in IFN-.beta..sub.1 abolishes its antiviral activity", Nature, 294:563-565 (Dec. 10, 1981).
Simon and Praag, "Inhibition of RNA Synthesis in Escherichia coli by Levorphanol", Proc. N. A. S., 51:877-883 (1964).
Snouwaert et al., "Effects of Site-Specific Mutations on Biologic Activities of Recombinant Human IL-2", J. Immunol., 146(2):585-591 (Jan. 15, 1991).
Snouwaert et al., "Role of Disulfide Bonds in Biologic Activity of Human Interleukin-6", J. Biol. Chem., 266(34):23097-23102 (Dec. 5, 1991).
Southern and Berg, "Transformation of Mammalian Cells to Antibiotic Resistance with a Bacterial Gene Under Control of the SV40 Early Region Promoter", J. Mol. Appl. Genet., 1:327-341 (1982).
Velan et al., "The Effect of Elimination of Intersubunit Disulfide Bonds on the Activity, Assembly, and Secretion of Recombinant Human Acetylcholinesterase", J. Biol. Chem., 266(35):23977-23984 (Dec. 15, 1991).
Wang et al., Site -Specific Mutagenesis of the Human Interleukin-2 Gene: Structure-Function Analysis of the Cysteine Residues, Science, 244:1431-1433 (Jun. 29, 1984).
Weiss and Olsson, "Cellular and Subcellular Localization of the Bactericidal/Permeability-Increasing Protein of Neutrophils", Blood, 69(2):652-659 (Feb. 1987).
Wetzel, "Harnessing disulfide bonds using protein engineering", TIBS., 12:478-482 (Dec. 1987).
Wilkinson et al., "Site-Directed Mutagenesis as a Probe of Enzyme Structure and Catalysis: Tyrosyl-tRNA Synthetase Cysteine-35 to Glycine-35 Mutation", Biochemistry, 22(15):3586-3594 (1983).
Winter et al., "Redesigning enzyme structure by site-directed mutagenesis:tyrosyl tRNA synthesis and ATP binding", Nature, 299:756-758 (Oct. 21, 1982).
Xu et al., "Transcription Termination and Chromatin Structure of the Active Immunoglobulin .sub.K Gene Locus", J. Biol. Chem., 261(8):3838-3845 (Mar. 15, 1986).
Zoller and Smith, "Oligonucleotide-Directed Mutagenesis of DNA Fragments Cloned into M13 Vectors", Meth. Enzymol., 100:468-500 (1983).
Baltaian Manik
Burke David
Grinna Lynn
Horwitz Arnold
Theofan Georgia
Hendricks Keith D.
Xoma Corporation
LandOfFree
Stable bactericidal/permeability-increasing protein products and does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Stable bactericidal/permeability-increasing protein products and, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Stable bactericidal/permeability-increasing protein products and will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1613838